AMG 073

ApprovedCompleted
0 views this week 0 watching Active
Interest: 43/100
43
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Hyperparathyroidism

Conditions

Hyperparathyroidism, Parathyroid Neoplasms

Trial Timeline

Apr 1, 2001 → —

About AMG 073

AMG 073 is a approved stage product being developed by Amgen for Hyperparathyroidism. The current trial status is completed. This product is registered under clinical trial identifier NCT00037518. Target conditions include Hyperparathyroidism, Parathyroid Neoplasms.

What happened to similar drugs?

12 of 20 similar drugs in Hyperparathyroidism were approved

Approved (12) Terminated (2) Active (8)
Cinacalcet HClKyowa KirinApproved
Alendronate 70mg weeklyMerckApproved
DenosumabAmgenApproved
Sensipar® + Vitamin DAmgenApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT00110929Phase 2Completed
NCT00037518ApprovedCompleted

Competing Products

20 competing products in Hyperparathyroidism

See all competitors
ProductCompanyStageHype Score
ASP7991 + Cinacalcet + PlaceboAstellas PharmaPhase 2
35
KHK7580 + KRN1493Kyowa KirinPhase 2/3
38
KHK7580Kyowa KirinPhase 1
29
KHK7580Kyowa KirinPhase 1/2
32
KHK7580Kyowa KirinPhase 3
40
KHK7580Kyowa KirinPhase 3
40
Cinacalcet HClKyowa KirinApproved
43
KHK7580 + Cinacalcet HydrochlorideKyowa KirinPhase 3
40
Placebo + KHK7580 low dose + KHK7580 middle dose + KHK7580 high dose + KRN1493Kyowa KirinPhase 2
35
Paricalcitol + CalcitriolAbbViePre-clinical
18
paricalcitol + maxacalcitol + paricalcitol placebo + maxacalcitol placeboAbbViePhase 3
40
Paricalcitol + CalcifediolAbbVieApproved
43
Paricalcitol + Darbepoetin alfaAbbVieApproved
43
Alendronate 70mg weeklyMerckApproved
35
EtelcalcetideAmgenPhase 3
40
Cinacalcet + PlaceboAmgenPhase 2
35
Cinacalcet + PlaceboAmgenPhase 3
40
Etelcalcetide + PlaceboAmgenPhase 1
29
Sensipar (Cinacalcet HCl)AmgenPhase 2
35
AMG 073 + PlaceboAmgenPhase 3
40